imipenem, anhydrous has been researched along with Tuberculosis, Drug-Resistant in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Camoin, L; Canaan, S; Cavalier, JF; Durand, T; Spilling, CD | 1 |
| Erber, J; Rothe, K; Schmid, RM; Schneider, J; Spinner, CD; Tschaikowsky, T; Weidlich, S | 1 |
| Chavan, VV; Dalal, A; Das, M; Ferlazzo, G; Isaakidis, P; Kalon, S; Mansoor, H; Meneguim, A; Nagaraja, S; Paryani, R; Singh, P; Thekkur, P | 1 |
| Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V | 1 |
| Berisio, R; Capparelli, R; Correale, S; Pedone, E; Ruggiero, A | 1 |
| Butler-Laporte, G; Menzies, D; Winters, N | 1 |
| Centis, R; D'Ambrosio, L; Dore, S; Esposito, S; Migliori, GB; Sotgiu, G; Spanevello, A; Tiberi, S | 1 |
| Abdo Arbex, M; Akkerman, OW; Alarcon Arrascue, E; Alarcon Guizado, V; Aleksa, A; Alffenaar, JW; Artsukevich, J; Auchynka, V; Bonini, EH; Caminero, JA; Centis, R; Chong Marín, FA; Collahuazo López, L; D'Ambrosio, L; De Lorenzo, S; de Vries, G; Dore, S; Gaga, M; Gualano, G; Kunst, H; Matteelli, A; Migliori, GB; Moschos, C; Palmieri, F; Papavasileiou, A; Payen, MC; Piana, A; Roby Arias, AJ; Scardigli, A; Skrahina, A; Solovic, I; Sotgiu, G; Spanevello, A; Sulis, G; Tadolini, M; Tiberi, S; Vargas Vasquez, D; Viggiani, P; White, V; Zumla, A | 1 |
| Chambers, HF; Hopewell, PC; Kawamura, M; Schecter, GF; Turner, J | 1 |
3 review(s) available for imipenem, anhydrous and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery.
Topics: Antitubercular Agents; Carboxylic Ester Hydrolases; Drug Design; Enzyme Inhibitors; Humans; Lactones; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Mycolic Acids; Organophosphorus Compounds; Orlistat; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2021 |
Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment.
Topics: Amoxicillin; Antitubercular Agents; Azithromycin; Cilastatin; Clarithromycin; Clavulanic Acid; HIV Infections; Humans; Imipenem; Isoxazoles; Macrolides; Meropenem; Mycobacterium tuberculosis; Oxazolidinones; Randomized Controlled Trials as Topic; Thienamycins; Thioridazine; Treatment Outcome; Tuberculosis, Multidrug-Resistant; World Health Organization | 2015 |
Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Topics: Antitubercular Agents; beta-Lactams; Carbapenems; Clinical Studies as Topic; Ertapenem; Extensively Drug-Resistant Tuberculosis; Humans; Imipenem; Meropenem; Thienamycins; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
6 other study(ies) available for imipenem, anhydrous and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report.
Topics: Amikacin; Antitubercular Agents; Diarylquinolines; Drug Resistance, Bacterial; Female; Humans; Imipenem; Levofloxacin; Macrolides; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Skin; Skin Diseases, Bacterial; Soft Tissue Infections; Soft Tissue Injuries; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Vietnam; Young Adult | 2020 |
Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Female; Home Care Services; Humans; Imipenem; India; Infection Control; Male; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Vascular Access Devices; Vomiting | 2020 |
Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
Topics: Adult; Cardiotoxicity; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Female; Humans; Imipenem; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Salvage Therapy; Sputum; Survival Rate; Tuberculosis, Multidrug-Resistant; Young Adult | 2019 |
Structures of free and inhibited forms of the L,D-transpeptidase LdtMt1 from Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Catalytic Domain; Crystallization; Crystallography, X-Ray; Imipenem; Mycobacterium tuberculosis; Peptidyl Transferases; Protein Binding; Recombinant Proteins; Tuberculosis, Multidrug-Resistant | 2013 |
Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Topics: Adult; Antitubercular Agents; Clavulanic Acid; Cohort Studies; Comparative Effectiveness Research; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Female; Humans; Imipenem; Male; Meropenem; Middle Aged; Sputum; Thienamycins; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
Imipenem for treatment of tuberculosis in mice and humans.
Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Female; Humans; Imipenem; Isoniazid; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2005 |